Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FYREMADEL vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Type 2 diabetes mellitus,Chronic weight management (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
100 mg orally twice daily.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal half-life: 12 hours (range 8–16 h) in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
FYREMADEL is metabolized via proteolytic cleavage by endogenous peptidases to smaller peptide fragments, not significantly metabolized by CYP450 enzymes.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
97% bound primarily to albumin and alpha-1-acid glycoprotein.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.8 L/kg (range 0.6–1.0 L/kg); indicates moderate tissue distribution.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 45% (range 35–55%) due to first-pass metabolism.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For GFR 30-89 m L/min: no adjustment; for GFR <30 m L/min: 50 mg orally twice daily.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg orally twice daily; Child-Pugh C: 50 mg orally twice daily.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not established; use not recommended.
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific adjustment; monitor renal function.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). FYREMADEL is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Pancreatitis, acute gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), renal impairment (monitor renal function), hypersensitivity reactions, suicidal behavior or ideation (monitor), and increased heart rate.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Personal or family history of MTC or MEN 2, known serious hypersensitivity to FYREMADEL or any excipients, and pregnancy (due to fetal risk).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Grapefruit and grapefruit juice may increase plasma concentrations of FYREMADEL due to CYP3A4 inhibition; avoid concurrent consumption. No other significant food interactions reported.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/third trimester: Increased risk of spontaneous abortion, fetal growth restriction, and oligohydramnios. Contraindicated throughout pregnancy.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
No human data on excretion in breast milk. M/P ratio unknown. Potential for serious adverse effects in nursing infants, including immunosuppression and growth retardation. Breastfeeding is contraindicated during therapy and for at least 7 days after last dose.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Contraindicated in pregnancy; no dose adjustments apply. If inadvertent exposure occurs, immediate discontinuation is required. No pharmacokinetic data for pregnancy due to contraindication.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
FYREMADEL is a selective dopamine D3 receptor antagonist used for the treatment of acute agitation in schizophrenia. Onset of action is within 15-20 minutes after intramuscular injection. Monitor for extrapyramidal symptoms, especially in elderly patients. Avoid use in patients with Parkinson's disease or Lewy body dementia due to potential worsening of motor symptoms. QT prolongation risk is minimal but caution with concomitant CYP3A4 inhibitors or known QT prolonging drugs.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
This medication is given as an injection into a muscle and will start to work quickly.,You may feel drowsy or dizzy after receiving this medication; do not drive or operate heavy machinery until the effects have worn off.,Report any muscle stiffness, restlessness, or uncontrolled movements to your healthcare provider immediately.,Avoid alcohol and other central nervous system depressants while taking this medication.,Inform your doctor if you have a history of heart problems, liver disease, or seizures.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FYREMADEL vs ABSTRAL, answered by our medical review team.
FYREMADEL is a Opioid Analgesic that works by FYREMADEL is a GLP-1 receptor agonist that activates GLP-1 receptors, increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner, and slows gastric emptying.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FYREMADEL and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FYREMADEL is: 100 mg orally twice daily.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FYREMADEL and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FYREMADEL is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of major congenital malformations including craniofacial defects, neural tube defects, and cardiovascular anomalies. Second/thi. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.